Yokohama Rubber and Zeon will construct a bench facility at Zeon’s Tokuyama Plant in Shunan City to demonstrate a highly efficient technology for generating butadiene from ethanol derived from plant materials. The facility will begin operating in 2026, and will collect various data for securing butadiene and for mass production. This initiative is one of two R&D themes selected in...
The four Japanese tire makers, Bridgestone, Sumitomo Rubber, Yokohama Rubber, and Toyo Tires, have released their fiscal 2024 financial results. Although market conditions were generally harsh, all four companies posted record-high sales and record-high operating income (Bridgestone posted adjusted operating income; Sumitomo Rubber and Yokohama Rubber posted operating income), thanks in part to a tailwind from a weaker yen. On...
Sumitomo Rubber and Mitsubishi Chemical will start collaboration on resource recycling of carbon black, one of the main raw materials for tires. Under this collaboration, Sumitomo Rubber will supply Mitsubishi Chemical with recycled materials, including rubber fragments generated in the tire manufacturing process as well as crushed and processed products from used tires. Mitsubishi Chemical will feed the recycled materials...
Bridgestone has decided to construct a pilot plant for precision pyrolysis of used tires on the premises of its Seki Plant in Gifu Prefecture, with the aim of implementing horizontal tire recycling in society. The plant will have a maximum processing capacity of 7,500 tons of used tires per year. It will establish and optimize a precision pyrolysis process and...
Bridgestone, Tokai Carbon, Kyushu University, and Okayama University have launched a joint project to produce carbon black (eco Carbon Black = eCB) with rubber-reinforcing properties comparable to virgin carbon black (vCB) derived from petroleum and coal by secondary processing of recovered carbon black (rCB) extracted from used tires and other polymer products containing rubber. This project is a part of...
Zeon has invested in Optieum Biotechnologies, a developer of innovative CAR T cells. Optieum is aiming to commercialize the world’s first innovative CAR T cell therapy for solid tumors. One of the cancer therapies classified as gene therapy, the new therapy is based on the Eumbody System technology developed at Ehime University, which can efficiently produce chimeric antigen receptors (CAR)...
Signup today for free.
You will receive a weekly or daily roundup on what has been published and will be up to date on special offers.
Please make sure to select your preferred sending frequency!
Note: We save your entered data to send the newsletter. You can always easily unsubscribe. More information on data handling: Privacy Policy.
Close window
